疏肝健脾方治疗2型糖尿病合并非酒精性脂肪肝肝郁脾虚证的临床研究
|
摘要
目的：探讨中医学对2型糖尿病合并非酒精性脂肪肝的认识,采用疏肝健脾方治疗2型糖尿病合并非酒精性脂肪肝,客观评价疏肝健脾方治疗2型糖尿病合并非酒精性脂肪肝的疗效及安全性,探讨其防治本病的机理。
方法：采用随机平行对照的研究方法,将符合2型糖尿病合并非酒精性脂肪肝肝郁脾虚证的患者,随机分为治疗组(30例)和对照组(30例)。在一般治疗和西药降糖、调脂、降酶的基础上,治疗组再予中药疏肝健脾方水煎剂每日1剂,分为早晚两次服用,疗程12周。治疗前后分别评价两组临床症状、体征的变化,及血糖(FBG、P2hBG)、糖化血红蛋白(HbA1c)、血脂(TC、TG、HDL-C、LDL-C)、肝脏生化(AST、ALT)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)和肝脏B超等指标的变化。全部数据以SPSS17.0统计软件进行统计学分析。
结果：确认并纳入的2型糖尿病合并非酒精性脂肪肝肝郁脾虚证患者共60例(治疗组和对照组各30例)。治疗前两组患者的年龄、性别、病程等基线数据经统计学处理无显著性差异,两组数据具有可比性(P>0.05)。疗效指标比较结果：①对体征、症状的改善：治疗组治疗后症状明显改善,总有效率达86.67%,对照组总有效率为60.00%。治疗组体征、症状的改善情况优于对照组(P<0.01)。②血糖指标：治疗组与对照组患者空腹血糖、餐后2小时血糖、糖化血红蛋白均明显降低,与治疗前比较均有显着性差异(P<0.01),且治疗组空腹血糖及餐后血糖降低优于对照组(P<0.05),治疗组糖化血红蛋白降低明显优于对照组(P<0.01)。③血脂指标：治疗组和对照组患者甘油三酯、总胆固醇、低密度脂蛋白与治疗前比较均明显下降(P<0.01),高密度脂蛋白明显升高(P<0.01),且治疗组调脂疗效明显优于对照组(P<0.01)。④肝功能指标：治疗组和对照组患者的谷丙、谷草转氨酶治疗后均在正常范围,且治疗组转氨酶降低程度明显优于对照组(P<0.01)。⑤空腹血清胰岛素和胰岛素抵抗指数指标：两组患者治疗后空腹血清胰岛素及胰岛素抵抗指数明显降低,与治疗前比有显著性差异(P<0.01)；治疗组空腹血清胰岛素降低较对照组有显著差异(P<0.01),胰岛素抵抗指数较对照组有差异(P<0.05)。⑥肝脏B超：治疗组患者B超下肝脏脂肪分度改善,与治疗前比较有显著性差异(P<0.05),而对照组治疗前后无明显差异(P>0.05)。⑦安全性指标：治疗组患者安全性指标均在正常范围。
结论：从初步临床研究来看,中西医结合治疗2型糖尿病合并非酒精性脂肪肝效果明显优于单纯西药治疗,中药治疗既可改善2型糖尿病合并非酒精性脂肪肝患者的临床症状,改善胰岛素抵抗、降低血糖、调节血脂、降低谷丙谷草转氨酶等,且安全、有效,具有广泛的应用前景,值得进一步深入研究。
Purpose:To discuss the understanding of traditional Chinese medicine about type2diabetes mellitus and non-alcoholic fatty liverdisease by using prescription of soothing liver and invigorating spleen. To observe the therapeutic efficacy of this method in treating the syndrome of liver qi depression and spleen dificiency in type2diabetes mellitus and non-alcoholic fatty liverdisease.
Methods:A randomized, controlled trial was conducted.60patients with the syndrome of liver qi depression and spleen deficiency in type2diabetes mellitus and non-alcoholic fatty liverdisease were randomly classified into two proups. Besides the basic of regular treatment and modern medicine,the patients of treated group (n=30) were treated by Chinese medicine while the patients of controlled groups (n=30) were not. Twelve weeks was a course of treatment. The observed indexes included both curative effect indexes, such as clinical symptoms, FBG, P2HBG, HbAlc, AST, ALT, TC, TG, HDL-C, LDL-C, HOMA-IR, liver type-B ultrasonic, and safety indexes, such as routine blood, urine and stool test,, the function of liver and kidney and harmful reaction. All data were analyzed by the SPSS17.0statistics software.
Results:Prior treatment, no differences were found in the gender, age, course of disease between the two groups.①The total effective rate of treated group's patients was86.7%, while the controlled group was60%. The treated group gained an advantage over the controlled group (P<0.01).②he fasting blood glucose, postprandial blood glucose of two groups were lowered(.P<0.01). And the treated group had an advantage than the controlled group(P<0.05). The HbAlc of two groups were lowered(P<0.01). And the treated group had an advantage than the controlled group(P<0.01).③ompared with pre-treatment, in two group patients'TG、TC、 LDL-C had a lowering(P<0.01), and HDL-C had marked increased(P<0.01). And the treated group had an advantage than the controlled group(P<0.01). That showes that the combination of western medicine and chinese medicine has the function of adjusting fat and it does much better than using western medicine effected in TG, TC, LDL-C and HDL-C.④he AST and ALT of two groups were lowered(P<0.01).And the treated group had an advantage than the controlled group(P<0.01).⑤ll of patients after treatment of FINS and HOMA-IR decreased significantly compared with before treatment, there were significant differences(P<0.01). And the treated grouppatients'FINS had an advantage than the controlled group(P<0.01),while HOMA-IR had an advantage than the controlled group(P<0.05).⑥The treatment group patients'liver B-mode ultrasonography had improved(p<0.05), while the control group showed no significant difference before and after treatment (P>0.05).⑦t the same time, Group therapy for patients with renal function tests were within the normal range.
Conclusion:Chinese medicine of method in soothing liver and invigorating spleen has a sure curative effected in treating type2diabetes mellitus and non-alcoholic fatty liver disease. It is worth studying deeply and developing further.
方法：采用随机平行对照的研究方法,将符合2型糖尿病合并非酒精性脂肪肝肝郁脾虚证的患者,随机分为治疗组(30例)和对照组(30例)。在一般治疗和西药降糖、调脂、降酶的基础上,治疗组再予中药疏肝健脾方水煎剂每日1剂,分为早晚两次服用,疗程12周。治疗前后分别评价两组临床症状、体征的变化,及血糖(FBG、P2hBG)、糖化血红蛋白(HbA1c)、血脂(TC、TG、HDL-C、LDL-C)、肝脏生化(AST、ALT)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)和肝脏B超等指标的变化。全部数据以SPSS17.0统计软件进行统计学分析。
结果：确认并纳入的2型糖尿病合并非酒精性脂肪肝肝郁脾虚证患者共60例(治疗组和对照组各30例)。治疗前两组患者的年龄、性别、病程等基线数据经统计学处理无显著性差异,两组数据具有可比性(P>0.05)。疗效指标比较结果：①对体征、症状的改善：治疗组治疗后症状明显改善,总有效率达86.67%,对照组总有效率为60.00%。治疗组体征、症状的改善情况优于对照组(P<0.01)。②血糖指标：治疗组与对照组患者空腹血糖、餐后2小时血糖、糖化血红蛋白均明显降低,与治疗前比较均有显着性差异(P<0.01),且治疗组空腹血糖及餐后血糖降低优于对照组(P<0.05),治疗组糖化血红蛋白降低明显优于对照组(P<0.01)。③血脂指标：治疗组和对照组患者甘油三酯、总胆固醇、低密度脂蛋白与治疗前比较均明显下降(P<0.01),高密度脂蛋白明显升高(P<0.01),且治疗组调脂疗效明显优于对照组(P<0.01)。④肝功能指标：治疗组和对照组患者的谷丙、谷草转氨酶治疗后均在正常范围,且治疗组转氨酶降低程度明显优于对照组(P<0.01)。⑤空腹血清胰岛素和胰岛素抵抗指数指标：两组患者治疗后空腹血清胰岛素及胰岛素抵抗指数明显降低,与治疗前比有显著性差异(P<0.01)；治疗组空腹血清胰岛素降低较对照组有显著差异(P<0.01),胰岛素抵抗指数较对照组有差异(P<0.05)。⑥肝脏B超：治疗组患者B超下肝脏脂肪分度改善,与治疗前比较有显著性差异(P<0.05),而对照组治疗前后无明显差异(P>0.05)。⑦安全性指标：治疗组患者安全性指标均在正常范围。
结论：从初步临床研究来看,中西医结合治疗2型糖尿病合并非酒精性脂肪肝效果明显优于单纯西药治疗,中药治疗既可改善2型糖尿病合并非酒精性脂肪肝患者的临床症状,改善胰岛素抵抗、降低血糖、调节血脂、降低谷丙谷草转氨酶等,且安全、有效,具有广泛的应用前景,值得进一步深入研究。
Purpose:To discuss the understanding of traditional Chinese medicine about type2diabetes mellitus and non-alcoholic fatty liverdisease by using prescription of soothing liver and invigorating spleen. To observe the therapeutic efficacy of this method in treating the syndrome of liver qi depression and spleen dificiency in type2diabetes mellitus and non-alcoholic fatty liverdisease.
Methods:A randomized, controlled trial was conducted.60patients with the syndrome of liver qi depression and spleen deficiency in type2diabetes mellitus and non-alcoholic fatty liverdisease were randomly classified into two proups. Besides the basic of regular treatment and modern medicine,the patients of treated group (n=30) were treated by Chinese medicine while the patients of controlled groups (n=30) were not. Twelve weeks was a course of treatment. The observed indexes included both curative effect indexes, such as clinical symptoms, FBG, P2HBG, HbAlc, AST, ALT, TC, TG, HDL-C, LDL-C, HOMA-IR, liver type-B ultrasonic, and safety indexes, such as routine blood, urine and stool test,, the function of liver and kidney and harmful reaction. All data were analyzed by the SPSS17.0statistics software.
Results:Prior treatment, no differences were found in the gender, age, course of disease between the two groups.①The total effective rate of treated group's patients was86.7%, while the controlled group was60%. The treated group gained an advantage over the controlled group (P<0.01).②he fasting blood glucose, postprandial blood glucose of two groups were lowered(.P<0.01). And the treated group had an advantage than the controlled group(P<0.05). The HbAlc of two groups were lowered(P<0.01). And the treated group had an advantage than the controlled group(P<0.01).③ompared with pre-treatment, in two group patients'TG、TC、 LDL-C had a lowering(P<0.01), and HDL-C had marked increased(P<0.01). And the treated group had an advantage than the controlled group(P<0.01). That showes that the combination of western medicine and chinese medicine has the function of adjusting fat and it does much better than using western medicine effected in TG, TC, LDL-C and HDL-C.④he AST and ALT of two groups were lowered(P<0.01).And the treated group had an advantage than the controlled group(P<0.01).⑤ll of patients after treatment of FINS and HOMA-IR decreased significantly compared with before treatment, there were significant differences(P<0.01). And the treated grouppatients'FINS had an advantage than the controlled group(P<0.01),while HOMA-IR had an advantage than the controlled group(P<0.05).⑥The treatment group patients'liver B-mode ultrasonography had improved(p<0.05), while the control group showed no significant difference before and after treatment (P>0.05).⑦t the same time, Group therapy for patients with renal function tests were within the normal range.
Conclusion:Chinese medicine of method in soothing liver and invigorating spleen has a sure curative effected in treating type2diabetes mellitus and non-alcoholic fatty liver disease. It is worth studying deeply and developing further.
引文
[1]廖二元.莫朝晖.内分泌学[M].下册.第2版.北京：人民卫生出版社,2007：1491-1504
[2]Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes:principles of pathogenesis and therapy. Lancet, 2005,365(9467)1333-1346.
[3]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3)：163-166.
[4]Koh JH,Shin YG,Nam SM,et al. Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic FattyLiver Disease in Type 2 Diabetic Patients[J].Diabetes Care,2009,32(1):147-152.
[5]Fan J G, Li F, Cai X B, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J. Gastroenterol. Hepatol,2007,22:1086-1091.
[6]周岖.2型糖尿病和非酒精性脂肪肝[J],中国临床医学.2007,10(5)：675.
[7]Buettner R, Ottinger I, Scholmerich J, et al. Preserveddirect hepatic insulin action in rats with diet-inducedhepatic steatosis[J]. Am J Physiol Endocrinol Metab,2004,286(5):E828-833.
[8]Bugianesi E, Gastaldelli A, Vanni E, et al. Insulinresistance in non-diabetic patients with non-alcoholic fatty liver disease:sites and mechanisms[J]. Diabetologia,2005,48:634-342.
[9]Reaven GM. Insulin resistance and compensatory hyperinsulinemia:role in hypertension, dyslipidemia, and coronary heart disease [J].Am Heart J,1991,121 (4 Pt2):1283 -1288.
[10]Sanyal AJ, Campbell2sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis:association of insulin resistance and mitochondria abnormalities. Gast roenterology,2001,120:118321197.
[11]Biden T J, Robinson D, Cordery D, et al. Chronic effects of fatty acids on pancreatic beta-cell function: new insights from functional genomics J[J].Diabetes,2004,53 (Suppl 1):S159-S165.
[12]Marchesini G,Marzocchi R.Metabolic syndrome and NASH [J].Clin Liver Dis,2007,11:105-117
[13]Ong J P,Younossi Z M.Epidemiology and natrual history of NAFLD and NASH[J].Clin Liver Dis,2007,11:1-16
[14]沈红,柳涛,张莉,等.非酒精性脂肪肝细胞损伤敏感性的机制[J].世界华人消化杂志,2010,18(7)：685-688.
[15]窦爱霞,陆伦根.胰岛素抵抗和非酒精性脂肪性肝病研究进展[J].世界华人消化杂志,2006,14(12)：1197-1202.
[16]马丽娜,冯明,周英智,等.非酒精性脂肪肝与胰岛素抵抗[J].临床肝胆病杂志,2010,26(2)：173-177.
[17]Nishitani Y,Okazaki S, Imabayashi K,et al.Saturated and monounsaturated fatty acids increase interleukin-loproduction in rat hepatocytes[J].Nihon Arukoru Yaku butsu Ifakkai Zasshi,2007,42:32-35.
[18]Bufianesi E,Manzini P,D'Antico S,et al.Relative contribution of iron burden,HFE mutations,and insulin resistance to fibrosis in nonalcoholic fatty liver[J].Hepatology,2004,39:179-187.
[19]王卓然,张秀英.非酒精性脂肪肝细胞损伤机制的研究进展[J].中国兽医杂志,2012,1(48)：50-52.
[20]窦爱霞,陆伦根.胰岛素抵抗和非酒精性脂肪性肝病研究进展[J].世界华人消化杂志,2006,14(12)：1197-1202.
[21]Cerasi E胰岛素生成,胰岛素分泌及2型糖尿病：问题的核心在于p细胞[J].中华内分泌代谢杂志,2005,21：194-198.
[22]颜红梅,高鑫,刘蒙,等.糖调节正常的非酒精性脂肪肝病患者p细胞功能与胰岛素敏感性变化[J].中华内分泌代谢杂志,2007,23(1)：12-15.
[23]张四青,钟树妹,郭经琴.非酒精性脂肪肝患者的胰岛素抵抗和胰岛p细胞功能的临床研究.井冈山大学学报。2010,31(5)：125-128.
[24]Gup te P, AmarapurkarD, Agal S, et al. Non - alcoholic steatohepatitis in type 2 diabetesmellitus[J]. Gastroenterol Hepatol,2004,19(8):854-858.
[25]Gup te P, AmarapurkarD, Agal S, et al. Non - alcoholic steatohepatitis in type 2 diabetesmellitus[J]. Gastroenterol Hepatol,2004,19(8):854-858.
[26]ORAL EA, SIMHA V, RU IZ E, et al. Lep tin - rep lacement ther2apy for lipodystrophy[J]. N Engl JMed, 2002,346:570-578.
[27]彭侠彪,陈海英,阮巍山,等.瘦素、胰岛素抵抗与非酒精性脂肪肝的关系[J].广东医学,2009,30(11)：1713-1714.
[28]KOTEISH A, D IEHL AM. Animalmodels of steatosis[J]. Semin LiverDis,2001,21 (1):89-104.
[29]JAVOR E D, GHANYM G, COCHRAN E K, et al. Lep tin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy[J].Hepatology,2005,41 (4):753-760.
[30]LAUBNER K, KIEFFER T J, LAM N T, et al. Inhibition of p rep roinsulin gene exp ression by lep tin induction of supp ressor of cytokine signaling 3 in pancreatic beta-cells[J]. Diabetes,2005,54:3410-3417.
[31]马向华,王维敏.非酒精性脂肪肝患者瘦素抵抗和胰岛素抵抗研究[J].中华肝脏病杂志,2004,12：651-655.
[32]张淑贵,焦亮,龚莹,等.2型糖尿病伴非酒精性脂肪肝临床分析[J].实用糖尿病杂志,2011,7(5)：15
[33]McKimmie R L, Daniel K R, Carr J J. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes:the Diabetes Heart Study[J].Am J Gastroenterol,2008,103(12):3036-8.
[34]Targher G, Marra F, Marchesini G.Increased risk of cardiovascular disease in non-alcoholic fatty liver disease:causal effect or epiphenomenon[J].Diabetologia,2008,51(11):1947-53.
[35]范建高,曾民德.脂肪肝[M].上海：上海医科大学出版社,2000：115-188
[36]王德峰,孙力,潘书梅,等.强化胰岛素治疗对2型糖尿病大鼠胰岛B细胞凋亡的影响[J].中国老年学杂志,2011,31：264-266
[37]Jacqu em inet S, B riaud I, Rouau It C, et al1 lnh ib it ion of insulin gene expression by Long-term exposu re of pan creatic beta cells to palm itate is dependent upon the presence of a st imu latory glu cose concen tration[J].M etabolism,2000,49(4):532-61
[38]杜娆,虞勋,盛小英.非酒精性脂肪肝研究进展[J].中国现代医药杂志,2009,11(6)：133-134.
[39]叶任高,陆再英.内科学[M].6版.北京：人民卫生出版社,2004.
[40]王战建,张耀,等罗格列酮对高糖高脂饮食诱导糖尿病大鼠脂肪肝的治疗作用[J].中国糖尿病杂志,2008,16(9)：529-532.
[41]LiY, XuW, L iao Z, et all lndu ct ion of long-term glycem ic con trol in newly diagnosed type 2 d iabetic p at ien ts is associated w ith im provem en t of B cell function[J].D iabetes C are,2008; 27(11):2579-6021.
[42]王德峰,孙力,苗国英,等.强化胰岛素治疗对2型糖尿病大鼠氧化应激及胰岛B细胞凋亡的影响[J].医学综述,2011,17(1)：146-149.
[43]Kahn SE. T he relat ive contribut ions of insulin resist ance and bet acell dysfun ction to the pathophysiology of Type 2 diabet es[J]. Dia2betologia,2003,46(1):3-19.
[44]Sievenpiper JL, Jenkins AL, Whitham DL, Vuksan V. Insulin resist ance:concept s, cont roversies, and th e role of nut rit ion [J].Can J Diet Pract Res,2002,63(1):20-32.
[45]Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis[J]. Hepatology,2004,39:188-196.
[46]Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition,fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab,2000,85:2767-2774.
[47]Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab,1992,74:1020-1026.
[48]Hattori Y,Suzuki K,Hattori S,et al.Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension,2006,47(6):1183-1188.
[49]Leclerc I.Woltersdorf WW,da Silva Xavier G,et al.Metformin, but not leptin,regulates AMP-activated protein kinase in pancreatic islets:impact on glucose-stimulated insulin secretion.Am J Physiol Endocrinol Metab,2004,286(6):E1023-E1031.
[50]Mayerson AB,Hundal Rs,Dufour S,et al.The effect s of rosiglitazone on insulin sensitivity,lipolysis,and hepatic and skeletal muscle triglyceride content in patient swith type 2 diabetes. Diabetes,2002,51:797-802.
[51]Kim J H,Lewin TM, Coleman RA. Expression and characterization of recombinant rat acyl2coA synt hetases 1,4,and 5. Selective inhibition by t riacsin C and t hiazolidinediones. J Biol Chem,2001,276:24667-24673
[52]Yu S,Mat susue K, Kashireddy P, et al. Adipocyte specific gene expression and adipogenic steatosis in t he mouse liver due to PPAR-y overexpression. J Bio Chem,2003,278:498-505.
[53]Doy CP,J ames OF. Improved nonalcoholic steatohepatitis after 48 weeks of t reatment wit h t he PPAR2gamma ligand rosiglitazone. Hepatology,2003,38:1008-1017.
[54]Li ZP, Yang S, Huang J,et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology,2003,37:343-350.
[55]黄文森.吡格列酮治疗2型糖尿病合并非酒精性脂肪肝病的临床观察[J].辽宁医学院学报,2010,31(2)：128-130.
[56]刘锐,伍娟娟,甘国兴,等多烯磷脂酰胆碱对非酒精性脂肪性肝病模型大鼠肝脏SREBP-lc与ABCA1蛋白表达的影响[J].广东医学.2011,32(18)：2376-2378.
[57]李红山,陈少东.多烯磷脂酰胆碱改善脂肪肝大鼠肝脏脂质沉积的作用机制研究[J].医学研究杂志,2010年,39(12)：73-77.
[58]陆斌.二甲双胍和谷胱甘肽联合治疗非酒精性脂肪肝疗效观察[J].中国现代医生,2011,48(33)：167-168,171.
[59]余进.还原型谷胱甘肽在非酒精性脂肪肝患者治疗中的作用.药物与临床.2011,8(35)：84-85.
[60]周仲英.中医内科学[M].第二版.北京：中国医中药出版社,2007：407-415.
[61]杨春波,黄可成,王大仁.现代中医消化病学[M].福州：福建科学技术出版社,2007.
[62]贾明珠.从痰瘀论治2型糖尿病性脂肪肝32例临床观察.山西中医[J].2011,27(2)：26-27
[63]齐贺彬.糖尿病脂肪肝与消渴病兼证“肝癖”及其中医治疗.中国临床医生[J].2006,34(5)：18-20
[64]张文龙,马新英,交艳.中西医结合治疗2型糖尿病合并高血脂症、脂肪肝的临床观察[J].中医药导报,2009,15(1)：21-22.
[65]于文亚.中西医结合治疗非酒精性脂肪肝合并2型糖尿病疗效观察.四川中医[J].2008,26(5)：64
[66]仝小林,赵林华,陈良,等.糖尿病中医药防治研究进展[J].药品评价,2009,6(12)：467-470
[67]乔娜丽,杨钦河,纪桂元,等.论肝郁脾虚是脂肪肝的基本发病病机[J].时珍国医国药,2008,19(5)：1238-1239.
[68]胡爱民,晏玲.糖肝煎治疗2型糖尿病并脂肪肝的临床观察[J].湖北中医杂志,2010,32(10)：16-17.
[69]第五永长,许建秦.胰岛素抵抗中医病机探讨[J].四川中医,2008,26(1)：6-8.
[70]孙刚,李晓玲.痰浊证型患者糖、脂等指标检测及其临床意义[J].贵阳中医学院学报,1997,19(3)：59.
[71]张永涛.论脾与2型糖尿病胰岛素抵抗的关系[J].河南中医,2001,21(6)：3.
[72]高天舒,晏丽丽,王英娜.新诊断2型糖尿病常见中医证型与非酒精性脂肪肝及其相关危险因素分析[J].辽宁中医杂志,2011,38(2).
[73]姜兆顺,张胜兰,寇天芹,等.2型糖尿病血瘀证患者血小板CD62p、CD63测定意义探讨[J].中国中西医结合杂志,1999,19(9)：527.
[74]陈贵海.肥胖与血瘀证形成的相关性研究.山东中医药大学学报[J].2001,26(2)：129.
[75]施赛珠,陈剑秋,张茂华,等.宏观与微观相结合研究糖尿病血瘀证[J].中医杂志,1997,38(4)：233.
[76]柴佩芳,胡德培,陈灏珠,等.糖尿病合并心脑血管疾病的多种因素[J].上海医科大学学报,1998,25(3)：240.
[77]洗慧.糖尿病从瘀治初探[J].中国医药学报,2000,15(2)：132.
[78]程秀萍,王建康.试述从脾论治2型糖尿病合并脂肪肝[J].浙江中医杂志.2010,45(3)：170.
[79]张金明,陈晓明.丹泽颗粒加减治疗糖尿病合并脂肪肝20例[J].黑龙江中医药.2008,2：23-24.
[80]刘竞芳,郭淑琴,任慧雅,张敏.化浊导滞、活血化瘀法治疗肥胖型糖尿病性脂肪肝临床观察[J].医学研究与教学,2010,27(5)：55-57.
[81]曹东义,李佃贵,裴林,等.浊毒理论借鉴了《内经》的清浊概念[J].河北中医,2010,32(3)：338-341.
[82]芮以融.桃红四物汤加减治疗糖尿病合并脂肪肝疗效观察[J].中国实验方剂学杂志,2010,16(6)：295-296.
[83]魏菊仙,陆榕影,余传隆,等.中医名方应用进展[M].北京：中国科学技术出版社,1991：272.
[84]吴凌康,史亮亮,王章流,等.益气养阴活血组方治疗2型糖尿病合并脂肪肝的临床研究[J].中华中医药杂,2011,26(4)：848-860.
[85]王娅玲.降糖清肝汤治疗2型糖尿病合并非酒精性脂肪肝30例临床观察[J].浙江中医杂志.2007,42(2)：82-83.
[86]李蓉,张春蓉,陈坤.健脾益气类中药治疗2型糖尿病胰岛素抵抗40例.陕西中医.2011,32(7)：866-868.
[87]刘亚军,王佳,王春生.加味四逆散治疗2型糖尿病脂肪肝肝损害临床观察.北京中医药.2009,28(7)：530-531.
[88]Ng TB, L iu F, Wang ZT. Antioxidative activity of natural products from p lants. L ife Sci 2000; 66 (8):709-723.
[89]Liu F, Ng TB. Antioxidative and free radical scavenging activitiesof selected medicinal herbs. Life Sci 2000; 66 (8):725-735.
[90]黄琳,陆付耳,杨小玉,等.黄连解毒汤对胰岛素抵抗大鼠肝脏线粒体氧化应激的影响[J].中国中西医结合杂志.2008,28(8)：725-727.
[91]Hu YY, Liu CH, Wang RP, et al. Protective actions of salvianolic acid A on hepatocyte injured by peroxidation in vitro[J]. World Gastroenterol,2000; 6(3):402-4.
[92]袁丁,张学敏,陈丽娟,等.丹参对糖尿病小鼠胰岛细胞的作用[J].福建中医学院学报.2010,20(3)：25-27.
[93]杨硕,娄金丽,等.葛根素治疗2型糖尿病KKAy小鼠肝脏损伤的实验研究[J].中国中西医结合杂志.2009,29(8)：707-710.
[94]Liu LZ, Cheung SC, Lan LL. et al. Berberine modulates insulin signaling transduction in insulin resistant cells [J]. Mol Cell Endocrinol,2010,317(1-2):148-153.
[95]杨小玉,陆付耳,黄琳,等.小檗碱对胰岛素抵抗大鼠氧化应激和内质网应激的影响[J].中国药理学通报,2008,24(9)：1138-1142.
[96]白瑞苗,郑贝贝,张日东,魏敬.小檗碱对非酒精性脂肪肝胰岛素抵抗及血清脂联素的影响[J].实用老年医学.2011,25(5)：423-426.
[97]陈志红,李堂,孙秀芳,等.黄芪对胰岛p细胞保护作用的研究[J].北京中医药大学学报,2009,32(3)：182-184.
[98]宗灿华,田丽梅.枸杞多糖对2型糖尿病胰岛素抵抗模型大鼠resistin基因表达的影响[J].药物生物技术,2008,15(4)：275-277.
[99]宋育林,曾民德,陆伦根,等.枸杞多糖对高脂饮食诱导的脂肪肝大鼠模型的影响[J].安徽医药,2007,11(3)：202-205.
[100]刘萍,何兰杰.枸杞多糖对糖尿病大鼠糖脂代谢的影响[J].宁夏医学院学报.2008,30(4)：427-428.
[101]施红,杨奇红,林雅,等.石斛及石斛合剂对糖尿病模型大鼠糖脂代谢的调整作用[J].上海中医药杂志.2004,38(12)：37-38.
[102]薛莉,陈宏,等.调理脾胃针法治疗2型糖尿病合并非酒精性脂肪肝30例[J].辽宁中医杂志.2011,38(10)：2029-2031.
[103]孙志,马丽,韩海荣.针灸对2型糖尿病大鼠胰岛素、抵抗素的作用研究[J].北京中医药大学学报.2010,33(10)：718-720.
[104]朱东晓.针灸对2型糖尿病患者血糖、血脂、胰岛素的影响[J].中医中药.2009,31：95-96.
[105]曲齐生,杨善军.针刺夹脊穴对2型糖尿病患者胰岛素抵抗疗效观察[J].中医药信息,2007,24(1)：50-51.
[106]袁爱红,刘志成,魏群利.针刺配耳穴对2型糖尿病伴脂代谢紊乱的调整作用[J].贵阳中医学院学报,2009,31(5)：22-24.
[107]中华医学会肝脏病学分会脂肪肝和酒精性脂肪肝病学组.非酒精性脂肪肝肝病诊疗指南[J].中华肝脏病组织,2010,2(4)：43-47.
[108]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002,227.
[109]中华中医药学会.糖尿病中医防治指南[M].北京：中国中医药出版社,2007：12.
[110]温赐祥,廖桂英,刘锋.脂肪肝的超声诊断与血脂浓度相关性分析[J].现代医用影像学,2005,14(3)：122-124.
[111]王昌壁.脂肪肝与血脂、血糖、血清酶的关系[J].职业与健康,2007,23(11)：922-923.
[112]陈东鸿,李平.柴胡及甘草酸对小鼠肝细胞凋亡的影响[J].第四军医大学学报,1998,19(3)：279.
[113]王胜春,王玲.柴胡及五灵丸对慢性肝损伤小鼠的影响[J].第四军医大学学报,2002,23(2)：133.
[114]李素婷,姜凌雪,周晓慧,等.柴胡皂苷一d对乙醇损伤原代培养大鼠肝细胞的保护作用及其机制研究[J].时珍国医国药,2008,19(11)：2752-2753.
[115]潘琳,熊佳鹏.柴胡皂苷d抗肝纤维化大鼠脂质过氧化作用的研究[J].中国中药杂志,2008,33,(8)：915-919.
[116]郑琳颖,潘竞锵,吕俊华.白芍总苷对脂肪肝大鼠增强胰岛素敏感性及抗脂肪肝作用[J].中国中药杂志,2008,33(20)：2385-2390□
[117]冯瑞儿,郑琳颖,吕俊华,等.白芍总苷对代谢综合征-高血压大鼠改善胰岛素敏感性、降压和抗氧化作用[J].中国临床药理学与治疗学,2010,15(2)：154-159.
[118]Studer L, Csete M,Lee SH,et al. Enhanced proliferation, survival,and dopaminergic differentiation of CNS precursors in loweredoxygen[J]. J Neurosci,2000;20 (19):7377-7383.
[119]钟小明,陈旭东,余鸿.当归药理作用的研究进展[J].四川解剖学杂志.2007,15(1)：44-46.
[120]张敏,高晓红.茯苓的药理作用及研究进展[J].北华大学学报.2008.9(1)：63-67.
[121]陈春霞.羧甲基茯苓多糖的保肝和催眠作用[J].食用菌,2003,(增刊)：46-47.
[122]尹镭,赵元昌,许瑞龄,等.茯苓对实验性肝硬变的治疗作用[J].山西医学院学报,1992,23(2)：101-103.
[123]宿廷敏,王敏娟,阮时宝白术的化学成分及药理作用研究概述[J].贵阳学院学报.2008,3(2).
[124]周德文.术类的药理和药效.国外医药·植物药分册[J].1996,11(3)：120-122.
[125]王蕊,李景君,徐京育.复方丹参饮对胰岛素抵抗型大鼠血管内皮细胞一氧化氮及内皮素的影响[J.中西医结合心脑血管病杂志,2010,2(8)2：191-192.
[126]李玉先,刘晓东,朱照静.半夏药理作用的研究述要[J].辽宁中医学院学报,2004,6(6)：459-460
[127]王志强,李炳超.半夏药理作用研究进展.山西医药杂志.2009,38(1)：65-67.
[128]兰凤英,何静春,赵颖,等.郁金抗四氯化碳致小鼠急性肝损伤的作用[J].中国康复理论与实践,2007,13(5)：444-446.
[129]Quiles JL,Mesa MD,Ramirez2Tortosa CL,et al. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty steak development in rabbits 1 [J].Arterioscler Thromb Vasc Bio,2002,22 (7):1225-1231.
[130]Nishikant AR,Naresh JG. Antidiabetic activity of hydro-ethanolic extract Of Cyperus rotundus in alloxan induced diabetes in rats [J]. Fitote rapia,2006,77:585-588.
[131]Bernard L, Andre T,Irene Z, et al. A dmnistration of Cyperus rotundus Tubers Extract prevents Weight Gain in obese Zueker rats[J].Phytother Res,2007,21:724-730.
[132]Christina AJM, Pillai PG, Chidambranthan N, et al. Modulating effect of Cyperus rotundus Linn, on ethanol induced damage [EB/OL].http:www.cabi.org,2006-04-01、2009-04-08.
[133]于辉,李春,甘庆贤.香陈皮的药理作用.生物磁学,2005,5(1)：44-45.
[2]Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes:principles of pathogenesis and therapy. Lancet, 2005,365(9467)1333-1346.
[3]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3)：163-166.
[4]Koh JH,Shin YG,Nam SM,et al. Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic FattyLiver Disease in Type 2 Diabetic Patients[J].Diabetes Care,2009,32(1):147-152.
[5]Fan J G, Li F, Cai X B, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J. Gastroenterol. Hepatol,2007,22:1086-1091.
[6]周岖.2型糖尿病和非酒精性脂肪肝[J],中国临床医学.2007,10(5)：675.
[7]Buettner R, Ottinger I, Scholmerich J, et al. Preserveddirect hepatic insulin action in rats with diet-inducedhepatic steatosis[J]. Am J Physiol Endocrinol Metab,2004,286(5):E828-833.
[8]Bugianesi E, Gastaldelli A, Vanni E, et al. Insulinresistance in non-diabetic patients with non-alcoholic fatty liver disease:sites and mechanisms[J]. Diabetologia,2005,48:634-342.
[9]Reaven GM. Insulin resistance and compensatory hyperinsulinemia:role in hypertension, dyslipidemia, and coronary heart disease [J].Am Heart J,1991,121 (4 Pt2):1283 -1288.
[10]Sanyal AJ, Campbell2sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis:association of insulin resistance and mitochondria abnormalities. Gast roenterology,2001,120:118321197.
[11]Biden T J, Robinson D, Cordery D, et al. Chronic effects of fatty acids on pancreatic beta-cell function: new insights from functional genomics J[J].Diabetes,2004,53 (Suppl 1):S159-S165.
[12]Marchesini G,Marzocchi R.Metabolic syndrome and NASH [J].Clin Liver Dis,2007,11:105-117
[13]Ong J P,Younossi Z M.Epidemiology and natrual history of NAFLD and NASH[J].Clin Liver Dis,2007,11:1-16
[14]沈红,柳涛,张莉,等.非酒精性脂肪肝细胞损伤敏感性的机制[J].世界华人消化杂志,2010,18(7)：685-688.
[15]窦爱霞,陆伦根.胰岛素抵抗和非酒精性脂肪性肝病研究进展[J].世界华人消化杂志,2006,14(12)：1197-1202.
[16]马丽娜,冯明,周英智,等.非酒精性脂肪肝与胰岛素抵抗[J].临床肝胆病杂志,2010,26(2)：173-177.
[17]Nishitani Y,Okazaki S, Imabayashi K,et al.Saturated and monounsaturated fatty acids increase interleukin-loproduction in rat hepatocytes[J].Nihon Arukoru Yaku butsu Ifakkai Zasshi,2007,42:32-35.
[18]Bufianesi E,Manzini P,D'Antico S,et al.Relative contribution of iron burden,HFE mutations,and insulin resistance to fibrosis in nonalcoholic fatty liver[J].Hepatology,2004,39:179-187.
[19]王卓然,张秀英.非酒精性脂肪肝细胞损伤机制的研究进展[J].中国兽医杂志,2012,1(48)：50-52.
[20]窦爱霞,陆伦根.胰岛素抵抗和非酒精性脂肪性肝病研究进展[J].世界华人消化杂志,2006,14(12)：1197-1202.
[21]Cerasi E胰岛素生成,胰岛素分泌及2型糖尿病：问题的核心在于p细胞[J].中华内分泌代谢杂志,2005,21：194-198.
[22]颜红梅,高鑫,刘蒙,等.糖调节正常的非酒精性脂肪肝病患者p细胞功能与胰岛素敏感性变化[J].中华内分泌代谢杂志,2007,23(1)：12-15.
[23]张四青,钟树妹,郭经琴.非酒精性脂肪肝患者的胰岛素抵抗和胰岛p细胞功能的临床研究.井冈山大学学报。2010,31(5)：125-128.
[24]Gup te P, AmarapurkarD, Agal S, et al. Non - alcoholic steatohepatitis in type 2 diabetesmellitus[J]. Gastroenterol Hepatol,2004,19(8):854-858.
[25]Gup te P, AmarapurkarD, Agal S, et al. Non - alcoholic steatohepatitis in type 2 diabetesmellitus[J]. Gastroenterol Hepatol,2004,19(8):854-858.
[26]ORAL EA, SIMHA V, RU IZ E, et al. Lep tin - rep lacement ther2apy for lipodystrophy[J]. N Engl JMed, 2002,346:570-578.
[27]彭侠彪,陈海英,阮巍山,等.瘦素、胰岛素抵抗与非酒精性脂肪肝的关系[J].广东医学,2009,30(11)：1713-1714.
[28]KOTEISH A, D IEHL AM. Animalmodels of steatosis[J]. Semin LiverDis,2001,21 (1):89-104.
[29]JAVOR E D, GHANYM G, COCHRAN E K, et al. Lep tin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy[J].Hepatology,2005,41 (4):753-760.
[30]LAUBNER K, KIEFFER T J, LAM N T, et al. Inhibition of p rep roinsulin gene exp ression by lep tin induction of supp ressor of cytokine signaling 3 in pancreatic beta-cells[J]. Diabetes,2005,54:3410-3417.
[31]马向华,王维敏.非酒精性脂肪肝患者瘦素抵抗和胰岛素抵抗研究[J].中华肝脏病杂志,2004,12：651-655.
[32]张淑贵,焦亮,龚莹,等.2型糖尿病伴非酒精性脂肪肝临床分析[J].实用糖尿病杂志,2011,7(5)：15
[33]McKimmie R L, Daniel K R, Carr J J. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes:the Diabetes Heart Study[J].Am J Gastroenterol,2008,103(12):3036-8.
[34]Targher G, Marra F, Marchesini G.Increased risk of cardiovascular disease in non-alcoholic fatty liver disease:causal effect or epiphenomenon[J].Diabetologia,2008,51(11):1947-53.
[35]范建高,曾民德.脂肪肝[M].上海：上海医科大学出版社,2000：115-188
[36]王德峰,孙力,潘书梅,等.强化胰岛素治疗对2型糖尿病大鼠胰岛B细胞凋亡的影响[J].中国老年学杂志,2011,31：264-266
[37]Jacqu em inet S, B riaud I, Rouau It C, et al1 lnh ib it ion of insulin gene expression by Long-term exposu re of pan creatic beta cells to palm itate is dependent upon the presence of a st imu latory glu cose concen tration[J].M etabolism,2000,49(4):532-61
[38]杜娆,虞勋,盛小英.非酒精性脂肪肝研究进展[J].中国现代医药杂志,2009,11(6)：133-134.
[39]叶任高,陆再英.内科学[M].6版.北京：人民卫生出版社,2004.
[40]王战建,张耀,等罗格列酮对高糖高脂饮食诱导糖尿病大鼠脂肪肝的治疗作用[J].中国糖尿病杂志,2008,16(9)：529-532.
[41]LiY, XuW, L iao Z, et all lndu ct ion of long-term glycem ic con trol in newly diagnosed type 2 d iabetic p at ien ts is associated w ith im provem en t of B cell function[J].D iabetes C are,2008; 27(11):2579-6021.
[42]王德峰,孙力,苗国英,等.强化胰岛素治疗对2型糖尿病大鼠氧化应激及胰岛B细胞凋亡的影响[J].医学综述,2011,17(1)：146-149.
[43]Kahn SE. T he relat ive contribut ions of insulin resist ance and bet acell dysfun ction to the pathophysiology of Type 2 diabet es[J]. Dia2betologia,2003,46(1):3-19.
[44]Sievenpiper JL, Jenkins AL, Whitham DL, Vuksan V. Insulin resist ance:concept s, cont roversies, and th e role of nut rit ion [J].Can J Diet Pract Res,2002,63(1):20-32.
[45]Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis[J]. Hepatology,2004,39:188-196.
[46]Pasquali R, Gambineri A, Biscotti D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition,fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab,2000,85:2767-2774.
[47]Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab,1992,74:1020-1026.
[48]Hattori Y,Suzuki K,Hattori S,et al.Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension,2006,47(6):1183-1188.
[49]Leclerc I.Woltersdorf WW,da Silva Xavier G,et al.Metformin, but not leptin,regulates AMP-activated protein kinase in pancreatic islets:impact on glucose-stimulated insulin secretion.Am J Physiol Endocrinol Metab,2004,286(6):E1023-E1031.
[50]Mayerson AB,Hundal Rs,Dufour S,et al.The effect s of rosiglitazone on insulin sensitivity,lipolysis,and hepatic and skeletal muscle triglyceride content in patient swith type 2 diabetes. Diabetes,2002,51:797-802.
[51]Kim J H,Lewin TM, Coleman RA. Expression and characterization of recombinant rat acyl2coA synt hetases 1,4,and 5. Selective inhibition by t riacsin C and t hiazolidinediones. J Biol Chem,2001,276:24667-24673
[52]Yu S,Mat susue K, Kashireddy P, et al. Adipocyte specific gene expression and adipogenic steatosis in t he mouse liver due to PPAR-y overexpression. J Bio Chem,2003,278:498-505.
[53]Doy CP,J ames OF. Improved nonalcoholic steatohepatitis after 48 weeks of t reatment wit h t he PPAR2gamma ligand rosiglitazone. Hepatology,2003,38:1008-1017.
[54]Li ZP, Yang S, Huang J,et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology,2003,37:343-350.
[55]黄文森.吡格列酮治疗2型糖尿病合并非酒精性脂肪肝病的临床观察[J].辽宁医学院学报,2010,31(2)：128-130.
[56]刘锐,伍娟娟,甘国兴,等多烯磷脂酰胆碱对非酒精性脂肪性肝病模型大鼠肝脏SREBP-lc与ABCA1蛋白表达的影响[J].广东医学.2011,32(18)：2376-2378.
[57]李红山,陈少东.多烯磷脂酰胆碱改善脂肪肝大鼠肝脏脂质沉积的作用机制研究[J].医学研究杂志,2010年,39(12)：73-77.
[58]陆斌.二甲双胍和谷胱甘肽联合治疗非酒精性脂肪肝疗效观察[J].中国现代医生,2011,48(33)：167-168,171.
[59]余进.还原型谷胱甘肽在非酒精性脂肪肝患者治疗中的作用.药物与临床.2011,8(35)：84-85.
[60]周仲英.中医内科学[M].第二版.北京：中国医中药出版社,2007：407-415.
[61]杨春波,黄可成,王大仁.现代中医消化病学[M].福州：福建科学技术出版社,2007.
[62]贾明珠.从痰瘀论治2型糖尿病性脂肪肝32例临床观察.山西中医[J].2011,27(2)：26-27
[63]齐贺彬.糖尿病脂肪肝与消渴病兼证“肝癖”及其中医治疗.中国临床医生[J].2006,34(5)：18-20
[64]张文龙,马新英,交艳.中西医结合治疗2型糖尿病合并高血脂症、脂肪肝的临床观察[J].中医药导报,2009,15(1)：21-22.
[65]于文亚.中西医结合治疗非酒精性脂肪肝合并2型糖尿病疗效观察.四川中医[J].2008,26(5)：64
[66]仝小林,赵林华,陈良,等.糖尿病中医药防治研究进展[J].药品评价,2009,6(12)：467-470
[67]乔娜丽,杨钦河,纪桂元,等.论肝郁脾虚是脂肪肝的基本发病病机[J].时珍国医国药,2008,19(5)：1238-1239.
[68]胡爱民,晏玲.糖肝煎治疗2型糖尿病并脂肪肝的临床观察[J].湖北中医杂志,2010,32(10)：16-17.
[69]第五永长,许建秦.胰岛素抵抗中医病机探讨[J].四川中医,2008,26(1)：6-8.
[70]孙刚,李晓玲.痰浊证型患者糖、脂等指标检测及其临床意义[J].贵阳中医学院学报,1997,19(3)：59.
[71]张永涛.论脾与2型糖尿病胰岛素抵抗的关系[J].河南中医,2001,21(6)：3.
[72]高天舒,晏丽丽,王英娜.新诊断2型糖尿病常见中医证型与非酒精性脂肪肝及其相关危险因素分析[J].辽宁中医杂志,2011,38(2).
[73]姜兆顺,张胜兰,寇天芹,等.2型糖尿病血瘀证患者血小板CD62p、CD63测定意义探讨[J].中国中西医结合杂志,1999,19(9)：527.
[74]陈贵海.肥胖与血瘀证形成的相关性研究.山东中医药大学学报[J].2001,26(2)：129.
[75]施赛珠,陈剑秋,张茂华,等.宏观与微观相结合研究糖尿病血瘀证[J].中医杂志,1997,38(4)：233.
[76]柴佩芳,胡德培,陈灏珠,等.糖尿病合并心脑血管疾病的多种因素[J].上海医科大学学报,1998,25(3)：240.
[77]洗慧.糖尿病从瘀治初探[J].中国医药学报,2000,15(2)：132.
[78]程秀萍,王建康.试述从脾论治2型糖尿病合并脂肪肝[J].浙江中医杂志.2010,45(3)：170.
[79]张金明,陈晓明.丹泽颗粒加减治疗糖尿病合并脂肪肝20例[J].黑龙江中医药.2008,2：23-24.
[80]刘竞芳,郭淑琴,任慧雅,张敏.化浊导滞、活血化瘀法治疗肥胖型糖尿病性脂肪肝临床观察[J].医学研究与教学,2010,27(5)：55-57.
[81]曹东义,李佃贵,裴林,等.浊毒理论借鉴了《内经》的清浊概念[J].河北中医,2010,32(3)：338-341.
[82]芮以融.桃红四物汤加减治疗糖尿病合并脂肪肝疗效观察[J].中国实验方剂学杂志,2010,16(6)：295-296.
[83]魏菊仙,陆榕影,余传隆,等.中医名方应用进展[M].北京：中国科学技术出版社,1991：272.
[84]吴凌康,史亮亮,王章流,等.益气养阴活血组方治疗2型糖尿病合并脂肪肝的临床研究[J].中华中医药杂,2011,26(4)：848-860.
[85]王娅玲.降糖清肝汤治疗2型糖尿病合并非酒精性脂肪肝30例临床观察[J].浙江中医杂志.2007,42(2)：82-83.
[86]李蓉,张春蓉,陈坤.健脾益气类中药治疗2型糖尿病胰岛素抵抗40例.陕西中医.2011,32(7)：866-868.
[87]刘亚军,王佳,王春生.加味四逆散治疗2型糖尿病脂肪肝肝损害临床观察.北京中医药.2009,28(7)：530-531.
[88]Ng TB, L iu F, Wang ZT. Antioxidative activity of natural products from p lants. L ife Sci 2000; 66 (8):709-723.
[89]Liu F, Ng TB. Antioxidative and free radical scavenging activitiesof selected medicinal herbs. Life Sci 2000; 66 (8):725-735.
[90]黄琳,陆付耳,杨小玉,等.黄连解毒汤对胰岛素抵抗大鼠肝脏线粒体氧化应激的影响[J].中国中西医结合杂志.2008,28(8)：725-727.
[91]Hu YY, Liu CH, Wang RP, et al. Protective actions of salvianolic acid A on hepatocyte injured by peroxidation in vitro[J]. World Gastroenterol,2000; 6(3):402-4.
[92]袁丁,张学敏,陈丽娟,等.丹参对糖尿病小鼠胰岛细胞的作用[J].福建中医学院学报.2010,20(3)：25-27.
[93]杨硕,娄金丽,等.葛根素治疗2型糖尿病KKAy小鼠肝脏损伤的实验研究[J].中国中西医结合杂志.2009,29(8)：707-710.
[94]Liu LZ, Cheung SC, Lan LL. et al. Berberine modulates insulin signaling transduction in insulin resistant cells [J]. Mol Cell Endocrinol,2010,317(1-2):148-153.
[95]杨小玉,陆付耳,黄琳,等.小檗碱对胰岛素抵抗大鼠氧化应激和内质网应激的影响[J].中国药理学通报,2008,24(9)：1138-1142.
[96]白瑞苗,郑贝贝,张日东,魏敬.小檗碱对非酒精性脂肪肝胰岛素抵抗及血清脂联素的影响[J].实用老年医学.2011,25(5)：423-426.
[97]陈志红,李堂,孙秀芳,等.黄芪对胰岛p细胞保护作用的研究[J].北京中医药大学学报,2009,32(3)：182-184.
[98]宗灿华,田丽梅.枸杞多糖对2型糖尿病胰岛素抵抗模型大鼠resistin基因表达的影响[J].药物生物技术,2008,15(4)：275-277.
[99]宋育林,曾民德,陆伦根,等.枸杞多糖对高脂饮食诱导的脂肪肝大鼠模型的影响[J].安徽医药,2007,11(3)：202-205.
[100]刘萍,何兰杰.枸杞多糖对糖尿病大鼠糖脂代谢的影响[J].宁夏医学院学报.2008,30(4)：427-428.
[101]施红,杨奇红,林雅,等.石斛及石斛合剂对糖尿病模型大鼠糖脂代谢的调整作用[J].上海中医药杂志.2004,38(12)：37-38.
[102]薛莉,陈宏,等.调理脾胃针法治疗2型糖尿病合并非酒精性脂肪肝30例[J].辽宁中医杂志.2011,38(10)：2029-2031.
[103]孙志,马丽,韩海荣.针灸对2型糖尿病大鼠胰岛素、抵抗素的作用研究[J].北京中医药大学学报.2010,33(10)：718-720.
[104]朱东晓.针灸对2型糖尿病患者血糖、血脂、胰岛素的影响[J].中医中药.2009,31：95-96.
[105]曲齐生,杨善军.针刺夹脊穴对2型糖尿病患者胰岛素抵抗疗效观察[J].中医药信息,2007,24(1)：50-51.
[106]袁爱红,刘志成,魏群利.针刺配耳穴对2型糖尿病伴脂代谢紊乱的调整作用[J].贵阳中医学院学报,2009,31(5)：22-24.
[107]中华医学会肝脏病学分会脂肪肝和酒精性脂肪肝病学组.非酒精性脂肪肝肝病诊疗指南[J].中华肝脏病组织,2010,2(4)：43-47.
[108]郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002,227.
[109]中华中医药学会.糖尿病中医防治指南[M].北京：中国中医药出版社,2007：12.
[110]温赐祥,廖桂英,刘锋.脂肪肝的超声诊断与血脂浓度相关性分析[J].现代医用影像学,2005,14(3)：122-124.
[111]王昌壁.脂肪肝与血脂、血糖、血清酶的关系[J].职业与健康,2007,23(11)：922-923.
[112]陈东鸿,李平.柴胡及甘草酸对小鼠肝细胞凋亡的影响[J].第四军医大学学报,1998,19(3)：279.
[113]王胜春,王玲.柴胡及五灵丸对慢性肝损伤小鼠的影响[J].第四军医大学学报,2002,23(2)：133.
[114]李素婷,姜凌雪,周晓慧,等.柴胡皂苷一d对乙醇损伤原代培养大鼠肝细胞的保护作用及其机制研究[J].时珍国医国药,2008,19(11)：2752-2753.
[115]潘琳,熊佳鹏.柴胡皂苷d抗肝纤维化大鼠脂质过氧化作用的研究[J].中国中药杂志,2008,33,(8)：915-919.
[116]郑琳颖,潘竞锵,吕俊华.白芍总苷对脂肪肝大鼠增强胰岛素敏感性及抗脂肪肝作用[J].中国中药杂志,2008,33(20)：2385-2390□
[117]冯瑞儿,郑琳颖,吕俊华,等.白芍总苷对代谢综合征-高血压大鼠改善胰岛素敏感性、降压和抗氧化作用[J].中国临床药理学与治疗学,2010,15(2)：154-159.
[118]Studer L, Csete M,Lee SH,et al. Enhanced proliferation, survival,and dopaminergic differentiation of CNS precursors in loweredoxygen[J]. J Neurosci,2000;20 (19):7377-7383.
[119]钟小明,陈旭东,余鸿.当归药理作用的研究进展[J].四川解剖学杂志.2007,15(1)：44-46.
[120]张敏,高晓红.茯苓的药理作用及研究进展[J].北华大学学报.2008.9(1)：63-67.
[121]陈春霞.羧甲基茯苓多糖的保肝和催眠作用[J].食用菌,2003,(增刊)：46-47.
[122]尹镭,赵元昌,许瑞龄,等.茯苓对实验性肝硬变的治疗作用[J].山西医学院学报,1992,23(2)：101-103.
[123]宿廷敏,王敏娟,阮时宝白术的化学成分及药理作用研究概述[J].贵阳学院学报.2008,3(2).
[124]周德文.术类的药理和药效.国外医药·植物药分册[J].1996,11(3)：120-122.
[125]王蕊,李景君,徐京育.复方丹参饮对胰岛素抵抗型大鼠血管内皮细胞一氧化氮及内皮素的影响[J.中西医结合心脑血管病杂志,2010,2(8)2：191-192.
[126]李玉先,刘晓东,朱照静.半夏药理作用的研究述要[J].辽宁中医学院学报,2004,6(6)：459-460
[127]王志强,李炳超.半夏药理作用研究进展.山西医药杂志.2009,38(1)：65-67.
[128]兰凤英,何静春,赵颖,等.郁金抗四氯化碳致小鼠急性肝损伤的作用[J].中国康复理论与实践,2007,13(5)：444-446.
[129]Quiles JL,Mesa MD,Ramirez2Tortosa CL,et al. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty steak development in rabbits 1 [J].Arterioscler Thromb Vasc Bio,2002,22 (7):1225-1231.
[130]Nishikant AR,Naresh JG. Antidiabetic activity of hydro-ethanolic extract Of Cyperus rotundus in alloxan induced diabetes in rats [J]. Fitote rapia,2006,77:585-588.
[131]Bernard L, Andre T,Irene Z, et al. A dmnistration of Cyperus rotundus Tubers Extract prevents Weight Gain in obese Zueker rats[J].Phytother Res,2007,21:724-730.
[132]Christina AJM, Pillai PG, Chidambranthan N, et al. Modulating effect of Cyperus rotundus Linn, on ethanol induced damage [EB/OL].http:www.cabi.org,2006-04-01、2009-04-08.
[133]于辉,李春,甘庆贤.香陈皮的药理作用.生物磁学,2005,5(1)：44-45.